The approval is based on the phase 3 QUAZAR AML-001 trial.
-
FDA approves azacitidine as maintenance therapy for AML -
AML: azacitidine-venetoclax combo extends survival in phase 3 VIALE-A study evaluated older patients ineligible for chemotherapy.
-
EMA green light for avapritinib for GIST, acalabrutinib for CLL Approvals from CHMP's July 2020 meeting.
-
Treatment considerations for APL in older adults Excerpt from an interview with Dr. Heidi Klepin.
-
Don't overlook treating older patients with acute promyelocytic leukemia, expert says An interview with Dr Heidi Klepin.
-
Tolerable safety profile and high response rate to blinatumomab in paediatric patients with r/r ALL
-
EHA 2020 – Fixed-duration ibrutinib in previously untreated CLL might spare immunotherapy for some Is it possible for fit patients with chronic lymphocytic leukemia and a good prognosis to skip immunochemotherapy in favor of ibrutinib?
-
EHA 2020 – ALL: chemotherapy conditioning before stem cell transplantation falls short Randomized global FORUM trial was stopped because of futility.
-
EHA 2020 – Phase 3 trial follow-up confirms venetoclax-obinutuzumab in patients with previously untreated CLL A more efficient regimen may be in sight for “typical” patients with newly diagnosed chronic lymphocytic leukemia.
-
EHA 2020 – At second look, improvements seen for elderly patients with acute myeloid leukemia in Denmark After adjusting for age, positive trends become apparent in the survival of elderly Danish AML patients between the years 2000 and 2016.
-
EHA 2020 – Combination of venetoclax and navitoclax explored in pretreated patients with ALL A phase 1 study with heavily pretreated patients with relapsed or refractory ALL reports promising response rates for the combination of 2 BCL-2-inhibitors.
-
EHA 2020 – Retinoic acid improves survival in elderly patients with acute myeloid leukemia Independent research from Freiburg University (Germany) shows significant benefits of add-on all-trans retinoic acid for frail patients with AML.
-
UK TARGET CML study finds little evidence that cardiovascular risk factors are considered during TKI management.
-
Secondary ALL: OS is worse than in de novo disease across all age groups Survival in ALL worsens with increasing age.